Matthew H Kulke, MD
Zoltan Kohn Professor, Medicine
Biography
Matthew Kulke, MD, is Chief of the Section of Hematology/Oncology in the Department of Medicine at Boston Medical Center and Zoltan Kohn Professor of Medicine at Boston University School of Medicine. In addition, he serves as Deputy Director of the BU-BMC Cancer Center and Medical Director of the Clinical Cancer Center at BMC.
Kulke is currently the Director of the Program in Neuroendocrine and Carcinoid Tumors at Dana-Farber Cancer Institute and Professor of Medicine at Harvard Medical School. A leader in the research and treatment of neuroendocrine tumors, he has received numerous awards for his accomplishments as a clinical investigator and provider of compassionate care to patients.
He has led national and international clinical trials to identify new therapeutic and diagnostic approaches to neuroendocrine tumors and gastrointestinal malignancies. In addition, he has published more than 100 peer-reviewed articles about neuroendocrine tumors.
Kulke received his undergraduate degree from Princeton University, his MD from University of California, San Francisco School of Medicine and a master’s degree in medical science from Harvard Medical School.
He completed his residency at Brigham and Women’s Hospital in Internal Medicine and a fellowhip in medical oncology at Dana-Farber Cancer Institute.
Kulke received the George Canellos Award for Clinical Investigation and the Ruth Brufsky Award for Pancreatic Cancer Research. He currently serves on the advisory board for the European Neuroendocrine Tumor Society, the executive committee of the North American Neuroendocrine Tumor Society, and chairs the Neuroendocrine Tumor Task force for the National Cancer Institute.
Other Positions
- Section Chief, Hematology & Medical Oncology, Medicine, Boston Medical Center
- Deputy Director, BU-BMC Cancer Center
- Medical Director, Clinical Cancer Center, Boston Medical Center
Education
- University of California, San Francisco, MD
- Harvard Medical School, MMS/MMSc
- Princeton University, BA
Publications
- Published on 9/9/2019
Cejas P, Drier Y, Dreijerink KMA, Brosens LAA, Deshpande V, Epstein CB, Conemans EB, Morsink FHM, Graham MK, Valk GD, Vriens MR, Castillo CF, Ferrone CR, Adar T, Bowden M, Whitton HJ, Da Silva A, Font-Tello A, Long HW, Gaskell E, Shoresh N, Heaphy CM, Sicinska E, Kulke MH, Chung DC, Bernstein BE, Shivdasani RA. Publisher Correction: Enhancer signatures stratify and predict outcomes of non-functional pancreatic neuroendocrine tumors. Nat Med. 2019 Sep 09. PMID: 31501535.
Read at: PubMed - Published on 8/13/2019
Kulke MH, Ruszniewski P, Van Cutsem E, Lombard-Bohas C, Valle JW, De Herder WW, Pavel M, Degtyarev E, Brase JC, Bubuteishvili-Pacaud L, Voi M, Salazar R, Borbath I, Fazio N, Smith D, Capdevila J, Riechelmann RP, Yao JC. A randomized, open-label, phase 2 study of everolimus in combination with pasireotide LAR or everolimus alone in advanced, well-differentiated, progressive pancreatic neuroendocrine tumors: COOPERATE-2 trial. Ann Oncol. 2019 Aug 13. PMID: 31407000.
Read at: PubMed - Published on 7/1/2019
Cejas P, Drier Y, Dreijerink KMA, Brosens LAA, Deshpande V, Epstein CB, Conemans EB, Morsink FHM, Graham MK, Valk GD, Vriens MR, Castillo CF, Ferrone CR, Adar T, Bowden M, Whitton HJ, Da Silva A, Font-Tello A, Long HW, Gaskell E, Shoresh N, Heaphy CM, Sicinska E, Kulke MH, Chung DC, Bernstein BE, Shivdasani RA. Enhancer signatures stratify and predict outcomes of non-functional pancreatic neuroendocrine tumors. Nat Med. 2019 Aug; 25(8):1260-1265. PMID: 31263286.
Read at: PubMed - Published on 5/14/2019
Fazio N, Martini JF, Croitoru AE, Schenker M, Li S, Rosbrook B, Fernandez K, Tomasek J, Thiis-Evensen E, Kulke M, Raymond E. Pharmacogenomic analyses of sunitinib in patients with pancreatic neuroendocrine tumors. Future Oncol. 2019 Jun; 15(17):1997-2007. PMID: 31084373.
Read at: PubMed - Published on 1/16/2019
Anthony LB, Kulke MH, Caplin ME, Bergsland E, Öberg K, Pavel M, Hörsch D, Warner RRP, O'Dorisio TM, Dillon JS, Lapuerta P, Kassler-Taub K, Jiang W. Long-Term Safety Experience with Telotristat Ethyl Across Five Clinical Studies in Patients with Carcinoid Syndrome. Oncologist. 2019 Aug; 24(8):e662-e670. PMID: 30651397.
Read at: PubMed - Published on 1/4/2019
Dasari A, Bergsland EK, Benson AB, Cai B, Huynh L, Totev T, Shea J, Duh MS, Neary MP, Dagohoy CG, Shih BE, Maurer VE, Chan J, Kulke MH. Treatment Patterns and Clinical Outcomes in Advanced Lung Neuroendocrine Tumors in Real-World Settings: A Multicenter Retrospective Chart Review Study. Oncologist. 2019 Aug; 24(8):1066-1075. PMID: 30610008.
Read at: PubMed - Published on 1/3/2019
Kulke MH, Benson AB, Dasari A, Huynh L, Cai B, Totev T, Roesner N, Duh MS, Neary MP, Maurer VE, Shih BE, Dagohoy CG, Chan J, Bergsland EK. Real-World Treatment Patterns and Clinical Outcomes in Advanced Gastrointestinal Neuroendocrine Tumors (GI NET): A Multicenter Retrospective Chart Review Study. Oncologist. 2019 Aug; 24(8):1056-1065. PMID: 30606883.
Read at: PubMed - Published on 1/1/2019
Yao JC, Garg A, Chen D, Capdevila J, Engstrom P, Pommier R, Van Cutsem E, Singh S, Fazio N, He W, Riester M, Patel P, Voi M, Morrissey M, Pavel ME, Kulke MH. Genomic profiling of NETs: a comprehensive analysis of the RADIANT trials. Endocr Relat Cancer. 2019 04 01; 26(4):391-403. PMID: 30667365.
Read at: PubMed - Published on 11/24/2018
Cella D, Beaumont JL, Hudgens S, Marteau F, Feuilly M, Houchard A, Lapuerta P, Ramage J, Pavel M, Hörsch D, Kulke MH. Relationship Between Symptoms and Health-related Quality-of-life Benefits in Patients With Carcinoid Syndrome: Post Hoc Analyses From TELESTAR. Clin Ther. 2018 12; 40(12):2006-2020.e2. PMID: 30477789.
Read at: PubMed - Published on 10/1/2018
da Silva A, Bowden M, Zhang S, Masugi Y, Thorner AR, Herbert ZT, Zhou CW, Brais L, Chan JA, Hodi FS, Rodig S, Ogino S, Kulke MH. Characterization of the Neuroendocrine Tumor Immune Microenvironment. Pancreas. 2018 10; 47(9):1123-1129. PMID: 30153220.
Read at: PubMed
View 189 more publications: View full profile at BUMC